b'Reference | Menus Gel and Capillary Electrophoresis MenuInvivoscribe offers assays that can be analyzed using twoApplied Biosystems (ABI) platforms e.g. 3130, 3500, 3500xL, 3500xL conventional methods of fragment analysis: gel electrophoresis orDx. Fragment analysis by capillary electrophoresis offers the ability capillary electrophoresis. to detect fragments with a high level of accuracy and analytical Next-Generation Sequencing Menu Gel electrophoresis kits offer a comparatively easy and inexpensivesensitivity and allows for greater sample throughput comparedto gel detection methods. In addition, capillary electrophoresis solution for clonality, translocation, and mutational testing anddetection often facilitates a more objective interpretation of results are often the method of choice for laboratories new to usingthan gel-based detection.Invivoscribe offers LymphoTrack and LymphoTrack Dx Assays forand the multiplexing capability to generate a sequencing library thatthese methods and techniques. PCR products are analyzed using the analysis of B- and T-cell clonality, somatic hypermutation, andcombines amplicons from different Invivoscribe LymphoTracknon-denaturing polyacrylamide gels (PAGE) and often require aThe table below summarizes which detection methods are available minimal residual disease studies**. Assays are designed for use onandLymphoTrack Dx Assays onto the same sequencing heteroduplex step for resolution of generated amplicons. for our clonality, translocation and FLT3 mutation assays either as both industry standard next-generation sequencing (NGS) platforms:chip, reducing per sample testing costs. RUO, CE-IVD, or IVD.the Illumina MiSeq and Thermo Fisher Scientific Ion PGMCapillary electrophoresis kits are supplied with fluorescently labeled and Ion S5 instruments. All LymphoTrack and LymphoTrack Dx Assays allow for fast and easyprimers, allowing the resulting PCR products to be analyzed on analysis and data visualization using the included bioinformatics Invivoscribe assays for the Illumina MiSeq platform offer the abilitysoftware. The LymphoTrack software sorts and assigns the sequencesCE-Marked IVD Assays Gel ABIto analyze up to twenty two samples and two controls per gene targetto their corresponding sample and provides information such as theIdentiClone IGH + IGK B-Cell Clonality Assay AVAILABLEAVAILABLE and the multiplexing capabilities to generate a sequencing libraryprevalence, gene segment usage, and the mutation rate (IGH Leader that combines amplicons from different Invivoscribe LymphoTrack andand IGH FR1 only). In addition, the Invivoscribe Minimal ResidualIdentiClone IGH Gene Clonality Assay AVAILABLEAVAILABLE LymphoTrack Dx Assays onto the same flow cell. Our included softwareDisease (MRD) Software allows for clonotype sequences to be trackedIdentiClone IGK Gene Clonality Assay AVAILABLEAVAILABLE then sorts and assigns the correct sequences to their correspondingin subsequent samples for research applications.sample.IdentiClone IGL Gene Clonality Assay AVAILABLEAVAILABLE The table below indicates which LymphoTrack (Research Use Only)IdentiClone TCRB Gene Clonality Assay AVAILABLEAVAILABLE Invivoscribe assays for the Ion PGM and Ion S5 platform offer theand LymphoTrack Dx (CE-IVD Marked) Assays are currently available ability to analyze up to ten samples and two controls per gene targetin 2020. IdentiClone T-Cell Receptor Gamma Gene Rearrangement Assay 2.0 NOT AVAILABLE AVAILABLE IdentiClone TCRD Gene Clonality Assay AVAILABLEAVAILABLE CE-Marked IVD AssaysMiSeqIon S5/PGMIdentiClone BCL1/J HTranslocation Assay AVAILABLENOT AVAILABLELymphoTrack Dx IGHV Leader Somatic Hypermutation Assays AVAILABLE NOT AVAILABLE IdentiClone BCL2/J HTranslocation Assay AVAILABLENOT AVAILABLELymphoTrack Dx IGH FR1 Assays AVAILABLE AVAILABLE LeukoStrat FLT3 Mutation Assay AVAILABLE NOT AVAILABLELymphoTrack Dx IGH FR2 Assays AVAILABLE AVAILABLE LeukoStrat FLT3 Mutation Assay 2.0 NOT AVAILABLE AVAILABLELymphoTrack Dx IGH FR3 Assays AVAILABLE AVAILABLE LeukoStrat CDx FLT3 Mutation Assay (CE-marked) NOT AVAILABLE AVAILABLELymphoTrack Dx IGH FR1/2/3 Assays AVAILABLE AVAILABLE IVD Assays Gel ABILymphoTrack Dx IGK Assays AVAILABLE AVAILABLE LeukoStrat CDx FLT3 Mutation Assay IVD (USA)NOT AVAILABLE AVAILABLELymphoTrack Dx TRG Assays AVAILABLE AVAILABLE LeukoStrat CDx FLT3 Mutation Assay (AUS)NOT AVAILABLE AVAILABLELymphoTrack Dx TRB Assays AVAILABLE PLEASE INQUIRE LeukoStrat CDx FLT3 Mutation Assay (JP) NOT AVAILABLE AVAILABLEResearch Use Only (RUO) Assays MiSeqIon S5/PGMLeukoStrat CDx FLT3 Mutation Assay (CE-IVD) NOT AVAILABLE AVAILABLELymphoTrack IGHV Somatic Hypermutation Assays AVAILABLE PLEASE INQUIRE Research Use Only (RUO) Assays Gel ABILymphoTrack IGH FR1 Assays AVAILABLE AVAILABLE FLT3 Mutation Assay AVAILABLE AVAILABLELymphoTrack IGH FR2 Assays AVAILABLE AVAILABLE IGH + IGK B-Cell Clonality Assay AVAILABLEAVAILABLE LymphoTrack IGH FR3 Assays AVAILABLE AVAILABLE IGH Gene Rearrangement Assay AVAILABLEAVAILABLE LymphoTrack IGH FR1/2/3 Assays AVAILABLE AVAILABLE IGH Gene Clonality Assay AVAILABLEAVAILABLE LymphoTrack IGK Assays AVAILABLE AVAILABLE IGH Somatic Hypermutation Assay v2.0 AVAILABLEAVAILABLE LymphoTrack TRG Assays AVAILABLE AVAILABLE IGL Gene Clonality Assay AVAILABLEAVAILABLE LymphoTrack TRB Assay AVAILABLE PLEASE INQUIRE TCRB Gene Clonality Assay AVAILABLEAVAILABLE T-Cell Receptor Gamma Gene Rearrangement Assay AVAILABLEAVAILABLE T-Cell Receptor Gamma Gene Rearrangement Assay 2.0 NOT AVAILABLE AVAILABLE TCRD Gene Clonality Assay AVAILABLEAVAILABLE BCL1/J HTranslocation Assay AVAILABLENOT AVAILABLEBCL2/J HTranslocation Assay AVAILABLENOT AVAILABLEBCL2/J Ht(14;18) Translocation Assay AVAILABLENOT AVAILABLEBCR/ABL t(9;22) Translocation Assay AVAILABLEAVAILABLE PML/RAR t(15;17) Translocation Assay AVAILABLEAVAILABLE CE-marked assays are in vitro diagnostic products and are not available for sale or use within North America. CE-marked assays are in vitro diagnostic products and are not available for sale or use within North America. IVD assays are in vitro diagnostic products, and are available for sale or use in regions indicated.**Minimal residual disease (MRD) applications are currently for research use only.152Invivoscribe 2021|153'